Call for Abstract

11th International Chronic Obstructive Pulmonary Disease Conference , will be organized around the theme “Freedom to Breathe, Starts with the Knowledge”

COPD CONFERENCE 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in COPD CONFERENCE 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms incorporate breathing trouble, cough, mucus production and wheezing. It is caused by long-term exposure to irritating gases or particulate issue, frequently from cigarette smoke. Individuals with COPD are at increased risk of creating coronary illness, lung cancer and a variety of different conditions. Emphysema and chronic bronchitis are the two most basic conditions that contribute to COPD. Chronic bronchitis is inflammation of the lining of the bronchial tubes, which convey air to and from the air sacs of the lungs. Emphysema is a condition in which the alveoli at the end of the smallest air passages of the lungs. Pulmonary Conferences provides a multidisciplinary to pulmonology researchers.


  • Track 1-1Pulmonology
  • Track 1-2Bronchiectasis
  • Track 1-3Obstructive lung disease
  • Track 1-4Pulmonary Emphysema
  • Track 1-5End-stage Lung Disease

Asthma and COPD have imperative similarities and differences. Both are chronic inflammatory diseases that include the small airways routes and cause airflow limitation, both outcome from quality condition collaborations and both are normally portrayed by mucus and bronchoconstriction. COPD affects both the aviation routes and the parenchyma, while asthma influences just the aviation routes. Both asthma and COPD include the small airways routes and the structural changes in the small airways routes are in charge of a great part of the physiological weakness that happens in these ailments. Lung Conferences envelop the fields of asthma and COPD which have important similarities and differences.


  • Track 2-1Airflow obstruction
  • Track 2-2Bronchospasm
  • Track 2-3Nocturnal Asthma
  • Track 2-4Chronic Obstructive Airways Disease

Pulmonary hypertension is a sort of hypertension that influences the arteries in lungs and the right side of heart. In one type of pulmonary hypertension, tiny arteries in your lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or devastated. This makes it harder for blood to move through your lungs, and raises pressure inside your lungs' courses. As the pressure builds, your heart's lower right chamber (right ventricle) must work harder to pump blood through your lungs, in the long run causing your heart muscle to debilitate and fail. In spite of the fact that a few kinds of pulmonary hypertension are not curable, treatment can help decrease symptoms and enhance quality of life. COPD Conferences concentrates on the impact of pulmonary hypertension.


  • Track 3-1Pulmonary arterial hypertension
  • Track 3-2Pulmonary Embolism
  • Track 3-3Pulmonary Venous Hypertension
  • Track 3-4Molecular pathology

The significant reason for an exacerbation is infection in the lungs (air sacs) or airways (breathing tubes). This infection is frequently from a virus, yet it might likewise happen from microbes or less basic sorts of organisms. Exacerbations can also occur from breathing in irritating substances from the earth like substantial air contamination or from severe allergies. Self-management and prevention for COPD will be advantageous for future exacerbation. COPD exacerbations can be harmful because they can make damage the lungs. COPD, keeping a compounding from happening can enable you to live a healthier life and diminish risk of death. Pulmonary Conferences envision the pulmonology.


  • Track 4-1Acute Exacerbation
  • Track 4-2Pathophysiology of exacerbations
  • Track 4-3Management of Exacerbation

Patients with chronic obstructive pulmonary disease are at increased risk for both the development of primary lung malignancy. Cigarette smoking is the principal hazard factor for advancement of lung disease. Passive exposure to tobacco smoke likewise can cause lung malignancy. Treatment of lung tumor can include a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation treatment and also newer experimental methods. Smoking suspension is the most vital measure that can keep the advancement of lung cancer. Lung Conferences concentrates on the risk factor for development of lung cancer.


  • Track 5-1Small-Cell Lung Carcinoma
  • Track 5-2Prognosis of Lung Cancer
  • Track 5-3Genetic susceptibility
  • Track 5-4Chronic inflammation

People with COPD will probably create pneumonia. Pneumonia is especially unsafe for individuals with COPD by causing an increased risk of respiratory failure. This is the point at which your body is either not getting enough oxygen or isn't effectively expelling carbon dioxide. Pneumonia and COPD can result in serious complications. Long term and even permanent damage can occur. Early treatment can help decrease these risks. The inflammation from the pneumonia can constrain your airflow, which can further damage your lungs. This can progress into acute respiratory failure, which can be fatal. COPD Conferences enlighten the recent advances in COPD and pulmonology research.


  • Track 6-1Complications
  • Track 6-2Epidemiology
  • Track 6-3Pathogenesis

Comprehensive pulmonary rehabilitation is an imperative part in the clinical management of people with chronic obstructive pulmonary disease. Pulmonary rehabilitation is a program of progressive exercise and education supervised by a physiotherapist for individuals with COPD. At pulmonary rehabilitation, you will also learn about: breathing techniques, medications, nutrition, relaxation, oxygen, travel, how to do ordinary undertakings with less shortness of breath, and how to stay healthy and keep away from COPD exacerbations. Lung Conferences provides global forum for discussion about new innovation of pulmonology research.


  • Track 7-1Exercise training
  • Track 7-2Nutritional counselling
  • Track 7-3Energy-conserving techniques
  • Track 7-4Breathing strategies
  • Track 7-5Psychological counseling

Tuberculosis and Chronic Obstructive Pulmonary Disease carry about a significant concern in terms of morbidity and mortality around the world. This spotlight on various parts of tuberculosis as far as the association with COPD such as in the advancement of chronic airflow obstruction as a sequel of active tuberculosis and assessing the key role of cigarette smoking in the pathogenesis of both conditions. Patients determined to have tuberculosis may regularly have extensive co-morbidity such as COPD and the impact of an underlying diagnosis of COPD on results in tuberculosis is also reviewed. COPD Conferences explores the new ideas and techniques of pulmonary therapy.


  • Track 8-1Airway obstruction
  • Track 8-2Genetic Vulnerability
  • Track 8-3Common Risk factors
  • Track 8-4Co-Morbidity on TB mortality

The objective of COPD therapeutics is to improve a patient's practical status and quality by protecting optimal lung function, enhancing indications, and keeping the recurrence of COPD exacerbations. At present, no medicines aside from lung transplantation have been appeared to significantly improve lung capacity or diminishing mortality; however, oxygen treatment and smoking cessation may decrease mortality. Once the diagnosis of COPD is established, it is essential to educate the patient about the disorder and to enable their dynamic interest for treatment. Bronchodilators are the establishment of any COPD treatment regimen. They work by enlarging aviation routes, accordingly diminishing airsac protection. Pulmonary Conferences provides a podium to bring forward the novel therapies for pulmonology.


  • Track 9-1Smoking Cessation
  • Track 9-2Corticosteroids
  • Track 9-3Oxygen Therapy
  • Track 9-4Pulmonary Rehabilitation

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in responsible for human and economic burden far and wide. Cigarette smoking is the basic hazard factor for COPD in the developed world, although other essential respiratory disorder incorporate word related exposures, air contamination, aviation route hyper responsiveness, asthma, and hereditary predisposition. In the vast majority of the world, epidemiology of COPD prevalence and mortality continue ascending in light of increases in smoking addiction, particularly by women and adolescents. COPD is moreover a basic explanation behind incapacity, and is associated with comorbid sicknesses, for instance, depression and cardiovascular disease, which adds to the huge economic burden related with this issue. Better public health and restorative interventions that objective both the hazard factors for COPD and look toward earlier mediation may decrease developing public health impact of COPD. COPD Conferences is an important key for both educational and clinical guidance for managing copd patients.


  • Track 10-1Morbidity of COPD
  • Track 10-2Molecular and Genetic Risk Factors
  • Track 10-3Occupational Exposure
  • Track 10-4Mortality of COPD
  • Track 10-5Social and economic factors

Chronic obstructive pulmonary disease (COPD) is a life-threatening condition. It influences lungs and ability to breathe. The pathophysiology of COPD is the physical changes associated with it; begin with harm to airways routes and the air sacs in lungs. It progresses from a cough with mucus to difficulty breathing. To understand pathophysiology of COPD, it is essential to understand the structure of the lungs. When you breathe in, air moves down in trachea through two tubes called bronchi. The bronchi branch out into smaller tubes called bronchioles. At the closures of the bronchioles are little air sacs called alveoli. Furthermore, toward the finish of alveoli are capillaries, which are modest veins. Pulmonary Conferences articulate the evolutions in the COPD and Pulmonology field.


  • Track 11-1Inflammatory mediators
  • Track 11-2Oxidative stress
  • Track 11-3Mucous Hypersecretion
  • Track 11-4Air trapping

COPD is one of the most common diseases in the world, and there is a global increase in prevalence, but there are no drugs available at present that halt the relentless progression of this disease. However, a better understanding of the cellular and molecular mechanisms that are involved in the underlying inflammatory and destructive processes has revealed several new targets for which drugs are now in development, and the prospects for finding new treatments are good. Lung Conferences will focus on the different techniques used in pulmonology.


  • Track 12-1Bronchodilators
  • Track 12-2Inhaled corticosteroids
  • Track 12-3LABA–LAMA

Even if an individual has never smoked or been unprotected to pollutants for an extended period of time, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known hereditary hazard factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1 in the circulatory system. Without the Alpha-1 Antitrypsin protein, white platelets start to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society proposes that every individual determined to have COPD be tested for Alpha-1. Pulmonary Conferences also discusses about different types of genes which may be a cause of pulmonary diseases.


  • Track 13-1Alpha1-antitrypsin
  • Track 13-2Alpha1-antichymotrypsin
  • Track 13-3Cystic fibrosis transmembrane regulator
  • Track 13-4Vitamin D-binding protein
  • Track 13-5Alpha2-macroglobulin

Individuals with COPD can be in risk for serious complications that can put their wellbeing in risk, as well as be fatal. Cor Pulmonale of COPD cut down limit edema (swelling) in a patient with COPD Complications is commonly a sign of cor pulmonale (pneumonic hypertension and right-sided heart failure). Acute COPD Exacerbations are depicted by an unexpected addition of manifestations. Cough and sputum production increases. At the point when respiratory failure occurs in a patient who gradually, there is a moderate decrease in lung capacity and rising levels of carbon dioxide in the blood. The growing carbon dioxide has a sedative effect in the patient, who gradually loses awareness and quits relaxing. Different difficulties of COPD incorporate pneumonia, polycythemia, and pneumothorax. Pneumonia caused by bacterial disease can prompt respiratory failure in these patients. Streptococcus pneumoniae is the most outstanding reason behind bacterial pneumonia in patients with COPD. Pneumothorax happens when a hole develops in the lung, empowering air to escape into the space between the lung and the chest wall and collapsing the lung. Polycythemia in COPD is the body's endeavour to adjust to decreased measure of blood oxygen by expanding the generation of oxygen-passing on red blood cells. While this might be useful temporarily, overproduction eventually clogs small blood vessels. Lung Conferences expresses various developing treatments for COPD.


  • Track 14-1End-stage Lung Disease
  • Track 14-2Cor Pulmonale
  • Track 14-3Pneumothorax
  • Track 14-4Lung cancer

Chronic obstructive pulmonary disease is related with increased risk of cardiovascular disease, for instance, heart failure or a heart attack. The lungs and the heart work solidly together to supply the oxygen; oxygen in the air comes into the lungs is moved into the circulation system, which the heart by then pushes out to rest of the body. However, diseases in both the heart and the lungs regularly go together. If person have COPD at that point there is a higher risk of having cardiovascular diseases. Comorbidities and chronic obstructive pulmonary disease (COPD) are pervasive, with cardiovascular disease being the most notable and significant. Risk factors for COPD and Cardiovascular Diseases such as smoking, low socioeconomic class, and a sedentary way of life contribute to the natural history of each of these conditions. COPD Conferences will focus on the scope of COPD related to cardiovascular diseases.


  • Track 15-1Pathogenesis
  • Track 15-2Vascular remodelling
  • Track 15-3Dynamic hyperinflation
  • Track 15-4Pulmonary artery catheterization
  • Track 15-5Respiratory Treatment and Dysrhythmias

Self-Management and Prevention of COPD interventions assist patients with chronic obstructive pulmonary disease (COPD) acquire and practise the skills they need to carry out disease particular medical regimens, guide changes in health behaviour and provide passionate help to empower patients to control their ailment. Patients with COPD affirmed by spirometry and symptoms and airflow obstruction should be monitored frequently to guide modification of treatment and to distinguish complications early. Pulmonary Conferences will be focused around the self-management support programmes should be collaborative between healthcare professionals and patients, to enable them to secure abilities to understand and manage with their medications and exacerbations of COPD, embrace healthier behaviours and deal with the social-emotional consequences of the disease.


  • Track 16-1Health Care Utilization
  • Track 16-2Managing medication
  • Track 16-3Adjusting Lifestyle
  • Track 16-4Managing symptoms

Depression and anxiety in COPD are standard in patients with chronic obstructive pulmonary disease (COPD), evaluations of their pervasiveness differ significantly. These likely reflect the variety of scales and techniques used to measure such symptoms. Patients with COPD with three or more comorbidities more likely to be frequently hospitalized and may die prematurely compared with COPD patients without comorbidities. An uplifted experience of dyspnoea is likely contributing segment to nervousness. Feelings of depression may be precipitated by the loss and grief related with the inability of COPD. Smoking has been related with nicotine addiction, and the variables that contribute to smoking may also predispose to anxiety and depressive disorders. The cause of depression and anxiety manifestations are multifactorial and include behavioural, social and biological factors. COPD Conferences paves a way towards a break-through in pulmonology research field.


  • Track 17-1Prevalence in COPD
  • Track 17-2Classification and diagnostic criteria
  • Track 17-3Clinical features and impact
  • Track 17-4Screening and diagnosis
  • Track 17-5Risk factors
  • Track 17-6Mechanism of potential association with COPD

A significant part of the pulmonary rehabilitation, research and pneumonic medication goes toward the youngest people from society-the newborns. For instance, the purpose behind pulmonary stenosis is a direct result of inappropriate pneumonic valve enhancement in the initial two months of fetal development. It's congenital but treatable. With a sound pulmonary stenosis diagnosis the heart valve can be replaced or repaired and children can develop normal healthy lives. Sleep apnea affects premature infants. A situation called apnea of prematurity exists when the child doesn't breath for 20 seconds or more. It is a pneumonic disease that can be treated with ventilation machines and medications. COPD Conferences explains about pediatric pulmonary, critical care and sleep which includes Pediatric emergencies, Pneumonia, Respiratory failure, Pediatric in-patient and critical care, Sepsis and Head Trauma & Concussion.


  • Track 18-1Pediatric Pulmonary Medicine
  • Track 18-2Pediatric Allergy
  • Track 18-3Sleep apnea
  • Track 18-4Pediatric Pulmonary Hypertension

There's currently now no solution for chronic obstructive pulmonary disease (COPD), yet pulmonary infections treatment and therapies can help moderate the development of the condition and control the symptoms. Drugs include: quit smoking, inhalers and pharmaceuticals – to help make breathing easier, pulmonary rehabilitation – a particular program of activity and education surgery or a lung transplant – although this is just a possibility for few individuals. A great part of the treatment for COPD incorporates self-management and prevention of COPD. Oxygen treatment can quality of life and is the main COPD treatment demonstrated to expand life. Surgery is a possibility for a few people with a few types of serious emphysema who aren't helped adequately by medications alone. Surgical options include: Lung volume reduction surgery, Lung transplant and Bullectomy. Lung Conferences will disclose the application of different treatments and therapies.


  • Track 19-1Quit Smoking and Avoid Lung Irritants
  • Track 19-2Oxygen Therapy
  • Track 19-3Surgery
  • Track 19-4Lung Transplant
  • Track 19-5Bullectomy

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide. COPD exacerbation is normally treated with anti-infection agents, systemic corticosteroids, and inhaled bronchodilators. COPD exacerbation was treated with standard treatment. Dynamic expiratory computed tomography of the chest was done, which uncovered associative tracheomalacia. COPD and tracheomalacia may exist together during recurrent exacerbations of COPD, and deferred finding can be related with extreme comorbidities. Ordering the appropriate imaging technique may help in the correct diagnosis and encourage appropriate management. COPD Conferences focus on the modern approaches of Pulmonology.


  • Track 20-1Physical Examination
  • Track 20-2Diagnostic Studies
  • Track 20-3Environmental hazards